# 12 Clinical and Translational Research Center

> **NIH NIH P30** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2021 · $336,390

## Abstract

PROJECT SUMMARY: CLINICAL AND TRANSLATIONAL RESEARCH CENTER (CTRC)
The Clinical and Translational Research Center (CTRC) is the dedicated MD Anderson site for complex
biologically-based new drug evaluation. With its 32-room nursing treatment center and adjacent full-function
research laboratory, the CTRC is an ideal location to perform intensive clinical trials with a focus on first-in-
human, phase I, and phase II studies requiring rigorous time points and pharmacologic testing. The CTRC
provides a distinct resource for physician-scientists and clinical investigators to develop new agents for cancer
treatment by offering coordination of multidisciplinary research, regulatory compliance, budget development,
intensive and time-sensitive monitoring of patients, phlebotomy, and prompt and accurate specimen processing,
storage, tracking, and shipment. The CTRC director, Filip Janku, MD, PhD; co-director, Daniel Karp, MD;
clinical administrative director, Brenda Brown, MSN, RN, OCN, NEA-BC; and assistant director, Passion Lockett,
DrPH, CCRC, provide leadership through planning, directing, and coordinating the integration of services and
transfer of knowledge between the CTRC and the other CCSG cores. Current services include biospecimen
collection and processing ranging from basic pharmacokinetic sampling to cell isolation and enumeration. Major
equipment includes 15 centrifuges, a biosafety cabinet, 6 ultra-low freezers, a cell culture analyzer, and an
AeroScout freezer monitoring system. Demand for services has increased by 98% since the previous grant cycle,
and the CTRC has met this demand by increasing efficiency and increasing capacity by expanding from 18 beds
to 32. Over the 6-year period, the CTRC facilitated 193 cancer center members who produced 184 publications,
with 92 (50%) in journals with IF >5 and 38 (21%) in journals with IF >10, including N Engl J Med, Lancet, Nature,
Nat Med, J Clin Oncol, and Cancer Cell. The CTRC's total operating budget in the current grant year (Yr43) is
$5,050,892, and the CCSG accounts for 4% ($213,297). A total of ~$600,000 was provided for research
equipment ($55,402) and renovations. In Yr42, 110 cancer center members used the CTRC, and 55% of all
usage was by peer review-funded users. All CCSG programs used the CTRC, with 38% of all usage by the
Developmental Therapeutics Program, followed by the Stem Cell Transplantation and Cellular Therapy Program
(13%). In Yr44, 4% ($218,178) is requested from the CCSG. The CTRC Specific Aims are: Aim 1: To leverage
the infrastructure and support for transformative high-impact early-phase clinical trials; Aim 2: To develop,
customize and implement a new clinical trials management system to increase efficiency, accountability,
transparency, plus data and sample integrity; Aim 3: To implement tools to evaluate patients' satisfaction and
deliver patient-centered clinical research; and Aim 4: To provide expertise, training and education to research
staff, faculty, and tr...

## Key facts

- **NIH application ID:** 10212260
- **Project number:** 5P30CA016672-45
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** Filip Janku
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $336,390
- **Award type:** 5
- **Project period:** 1996-08-28 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10212260

## Citation

> US National Institutes of Health, RePORTER application 10212260, 12 Clinical and Translational Research Center (5P30CA016672-45). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10212260. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*